PMID- 33627254
OWN - NLM
STAT- MEDLINE
DCOM- 20220113
LR  - 20220113
IS  - 1873-460X (Electronic)
IS  - 1056-8727 (Linking)
VI  - 35
IP  - 5
DP  - 2021 May
TI  - Adiponectin predicts the antioxidant capacity and size of high-density 
      lipoprotein (HDL) in individuals with diabetes mellitus.
PG  - 107856
LID - S1056-8727(21)00010-6 [pii]
LID - 10.1016/j.jdiacomp.2021.107856 [doi]
AB  - AIMS: The relationship between adiponectin and type 2 diabetes mellitus (T2DM) is 
      established; however the evidence on its role in high-density lipoprotein (HDL) 
      functionality is still scant. The aim of this study was to assess the association 
      of adiponectin with HDL functionality especially on the antioxidant capacity and 
      HDL subfractions in individuals with T2DM. METHODS: This case-control study 
      enrolled 356 individuals who were divided into two groups: diabetics [T2DM 
      (n = 188)] and non-diabetic [nT2DM (n = 168)]. The association of adiponectin 
      level on HDL functionality parameters was done in function of the cut-off point 
      for adiponectin [percentile p < 75 = 12.9 mug/mL versus p >/= 75 = 12.9 mug/mL] and 
      multiple adjustments applied in the logistic regression models. RESULTS: Body 
      mass index (BMI), waist circumference (WC) and body fat mass (FM) were higher in 
      T2DM. The larger HDL particles (HDL(LARGE)) were lower in T2DM group in 
      comparison with nT2DM (28.20% versus 30.40%; p = 0.016). Individuals with T2DM 
      and simultaneous highest adiponectin (p >/= 75) had 2.25 OR (95% CI = 1.03-4.91) 
      and 5.14 OR (95% CI = 2.37-11.15) to present higher HDL-C and HDL(LARGE) 
      concentrations. After adjustment for multiple confounders, high level of 
      adiponectin was independently related with improvement of the HDL antioxidant 
      capacity (OR = 2.78; 95% CI = 1.16-6.67). CONCLUSIONS: High adiponectin level 
      associates with a lesser negative impact of T2DM on HDL functionality by increase 
      in APO AI, particles size, and cholesterol content. On the same token, higher 
      adiponectin was associated with greater odds to have high antioxidant capacity.
CI  - Copyright (c) 2021 Elsevier Inc. All rights reserved.
FAU - Dias, G D
AU  - Dias GD
AD  - Department of Nutrition, Faculty of Public Health, University of Sao Paulo 
      (FSP-USP), Sao Paulo, Brazil.
FAU - Cartolano, F C
AU  - Cartolano FC
AD  - Department of Nutrition, Faculty of Public Health, University of Sao Paulo 
      (FSP-USP), Sao Paulo, Brazil.
FAU - Freitas, M C P
AU  - Freitas MCP
AD  - Department of Nutrition, Faculty of Public Health, University of Sao Paulo 
      (FSP-USP), Sao Paulo, Brazil.
FAU - Santa-Helena, E
AU  - Santa-Helena E
AD  - University of Blumenau, Santa Catarina, Brazil.
FAU - Markus, M R P
AU  - Markus MRP
AD  - Universitatsklinikum Greifswald, Greifswald, Germany.
FAU - Santos, R D
AU  - Santos RD
AD  - Lipid Clinic, Heart Institute (InCor), University of Sao Paulo Medical School 
      Hospital (HC-FMUSP), Sao Paulo, Brazil.
FAU - Damasceno, N R T
AU  - Damasceno NRT
AD  - Department of Nutrition, Faculty of Public Health, University of Sao Paulo 
      (FSP-USP), Sao Paulo, Brazil. Electronic address: nagila@usp.br.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210122
PL  - United States
TA  - J Diabetes Complications
JT  - Journal of diabetes and its complications
JID - 9204583
RN  - 0 (Adiponectin)
RN  - 0 (Antioxidants)
RN  - 0 (Cholesterol, HDL)
RN  - 0 (Lipoproteins, HDL)
SB  - IM
MH  - *Adiponectin/blood
MH  - Antioxidants
MH  - Case-Control Studies
MH  - Cholesterol, HDL
MH  - *Diabetes Mellitus, Type 2/blood
MH  - Humans
MH  - Lipoproteins, HDL/*blood
OTO - NOTNLM
OT  - Adiponectin
OT  - Antioxidant capacity
OT  - High-density lipoprotein
OT  - Lipoprotein size
OT  - Type 2 diabetes mellitus
COIS- Declaration of competing interest RDS has received honoraria related to 
      consulting, research and/or speaker activities from: Ache, Amgen, Astra Zeneca, 
      Esperion, EMS, Kowa, Novo-Nordisk, Merck, MSD, Pfizer, PTC and Sanofi/Regeneron. 
      Others have none to declare.
EDAT- 2021/02/26 06:00
MHDA- 2022/01/14 06:00
CRDT- 2021/02/25 05:34
PHST- 2020/09/19 00:00 [received]
PHST- 2020/12/09 00:00 [revised]
PHST- 2021/01/03 00:00 [accepted]
PHST- 2021/02/26 06:00 [pubmed]
PHST- 2022/01/14 06:00 [medline]
PHST- 2021/02/25 05:34 [entrez]
AID - S1056-8727(21)00010-6 [pii]
AID - 10.1016/j.jdiacomp.2021.107856 [doi]
PST - ppublish
SO  - J Diabetes Complications. 2021 May;35(5):107856. doi: 
      10.1016/j.jdiacomp.2021.107856. Epub 2021 Jan 22.